Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $34.94

Key Points

• Dyne Therapeutics, Inc. has received an average rating of "Buy" from 17 research firms, with a consensus price objective of $34.94.
• CEO John Cox purchased 100,000 shares of the company's stock for $911,000, increasing his ownership by 70.33%.
• Institutional investors own 96.68% of Dyne Therapeutics, indicating strong confidence from large investment firms in the company's future.

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have earned a consensus recommendation of "Buy" from the sixteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $33.80.

Several equities analysts recently issued reports on the company. Robert W. Baird reduced their price objective on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 18th. Stifel Nicolaus cut their target price on Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Oppenheimer reduced their price objective on shares of Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating for the company in a report on Wednesday, August 6th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th.

Insider Buying and Selling at Dyne Therapeutics

In other news, CEO John Cox acquired 100,000 shares of the firm's stock in a transaction on Monday, July 14th. The shares were purchased at an average cost of $9.11 per share, with a total value of $911,000.00. Following the acquisition, the chief executive officer directly owned 242,179 shares in the company, valued at $2,206,250.69. This represents a 70.33% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 14.14% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DYN. Summit Investment Advisors Inc. grew its holdings in shares of Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after purchasing an additional 721 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Dyne Therapeutics by 11.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company's stock worth $91,000 after buying an additional 955 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Dyne Therapeutics by 5.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock worth $237,000 after buying an additional 1,115 shares during the last quarter. Arizona State Retirement System raised its position in Dyne Therapeutics by 9.2% in the first quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after purchasing an additional 1,481 shares during the last quarter. Finally, CWM LLC raised its position in Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company's stock valued at $29,000 after purchasing an additional 1,900 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN traded down $0.17 on Tuesday, reaching $12.33. 250,016 shares of the company were exchanged, compared to its average volume of 2,633,166. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $47.45. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -3.21 and a beta of 1.08. The company has a 50-day moving average of $10.51 and a 200-day moving average of $11.30.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. Equities analysts forecast that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.